Abaloparatide dosage in published studies and labels

These are the doses used for Abaloparatide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.

Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.

Last checked against primary sources: November 7, 2026

Studied regimens and sources

Abaloparatide has an FDA-approved human dosage as Tymlos: 80 mcg once daily by subcutaneous injection into the area around the navel, for postmenopausal women with osteoporosis at high risk for fracture and to increase bone density in men with osteoporosis at high risk. The label says safety and efficacy have not been evaluated beyond 2 years, and use for more than 2 years in a lifetime is not recommended.

FDA Approved

Dosage evidence summary for Abaloparatide
Human dosing established	Yes
Studied dose range	80 mcg once daily
Route	Subcutaneous
Frequency	Once daily, at about the same time each day
Duration studied	Not more than 2 years in a lifetime
Half-life	About 1 hour (Tymlos label)
Evidence level	FDA Approved
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Abaloparatide, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
FDA label — Tymlos, osteoporosisFDA-approved label · FDA prescribing information	Postmenopausal women with osteoporosis at high risk for fracture; men with osteoporosis at high risk for fracture	80 mcg	Subcutaneous, periumbilical region of the abdomen, rotating the site daily; not intravenous or intramuscular	Once daily	Not more than 2 years in a lifetime	Reduces the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis, and increases bone density in men; the label's 18-month placebo-controlled study enrolled 824 women on 80 mcg and 821 on placebo	TYMLOS (abaloparatide) injection — FDA prescribing information, DailyMed

Where sources disagree

Abaloparatide is an analogue of PTHrP(1-34), parathyroid hormone-related peptide. It is not teriparatide, and the two labels set different doses (80 mcg and 20 mcg daily) and different limits on treatment length.
The label lists osteosarcoma under Warnings and Precautions and says to avoid abaloparatide in people at higher baseline risk, such as those with open growth plates, Paget's disease, bone metastases or skeletal cancer, or prior radiation to the skeleton. It also warns about orthostatic hypotension (the first doses are given where the person can sit or lie down), hypercalcaemia and severe allergic reactions.
The licensed product is a prefilled pen of 3120 mcg in 1.56 mL that delivers 30 doses of 80 mcg in 40 microlitres each. Research-labelled abaloparatide powder vials are not this product, and the label does not describe them.